Alogliptin/pioglitazone

Drug Profile

Alogliptin/pioglitazone

Alternative Names: Alogliptin/Actos; Incresync; Liovel HD; Liovel LD; NesinaAct; Oseni; Pioglitazone/alogliptin; SYR 322/pioglitazone

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Nitriles; Piperidines; Pyrimidinones; Thiazolidinediones
  • Mechanism of Action CD26 antigen inhibitors; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 22 Jun 2015 Launched for Type-2 diabetes mellitus in Croatia, Estonia, Finland, Hungary, South Korea, Latvia, Ireland, Italy, Lithuania, Slovakia, Slovenia, Malta, Sweden, Australia, Austria, Denmark and Hong Kong (PO) before June 2015
  • 18 Jun 2015 No recent reports on development identified - Preregistration for Type-2 diabetes mellitus in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top